PMID- 36529735
OWN - NLM
STAT- MEDLINE
DCOM- 20230106
LR  - 20230106
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Dec 19
TI  - Worsening effect of testosterone deficiency on males with heart failure with 
      preserved ejection fraction.
PG  - 321
LID - 10.1186/s12902-022-01249-3 [doi]
LID - 321
AB  - BACKGROUND: Heart failure with preserved ejection fraction (HFpEF)is challenging. 
      Patients usually have normal LV size and ejection fraction. This clinical 
      syndrome develops from a complex interaction of several risk factors that cause 
      organ dysfunction and clinical symptoms. There's evidence that testosterone 
      deficiency is associated with a worse cardiometabolic profile and increased 
      inflammatory markers. We thought that these changes might have an impact on heart 
      failure pathogenesis. We aimed to study the relationship between testosterone 
      level and symptoms in HFpEF. METHODS: We studied 120 male patients with HFpEF. 
      According to New York Heart Association (NYHA), patients were classified into I, 
      II and III classes; class IV patients were excluded. All patients were subjected 
      to clinical and echocardiographic examinations. In addition, we measured serum 
      testosterone, cardio-metabolic profile, intracellular adhesive 
      molecule-1(ICAM-1), P-selectin and nitric oxide (NO) levels. RESULTS: Patients 
      with testosterone deficiency had worse NYHA class and higher BNP P = (0.001). 
      Additionally, they had a significantly worse metabolic profile; higher total 
      cholesterol, triglycerides, LDL cholesterol, fasting insulin and HOMA-IR 
      P = (0.005, 0.001, 0.001, 0.001), respectively. Also, they had higher 
      inflammatory markers and worse endothelial functional parameters; (ICAM-1, NO and 
      P- selectin) P = (0.001). Age, BNP and testosterone deficiency can be used as 
      independent predictors of NYHA class III symptoms with a Testosterone cutoff 
      value of 2.7 ng/ml. CONCLUSION: Testosterone deficiency could be used as an 
      independent predictor of symptom severity in HFpEF, and it aggravates systemic 
      inflammation and endothelial dysfunction in these patients.
CI  - (c) 2022. The Author(s).
FAU - Hamam, Ahmed
AU  - Hamam A
AD  - Department of internal medicine, Armed Forces College of Medicine, Cairo, Egypt.
FAU - Abou-Omar, Mahmoud
AU  - Abou-Omar M
AD  - Cardiovascular medicine department, Faculty of Medicine, Tanta University, Tanta, 
      31511, Egypt.
FAU - Rabah, Hanem
AU  - Rabah H
AD  - Faculty of Medicine, Department of medical biochemistry, Tanta University, Tanta, 
      Egypt.
FAU - Khattab, Haidy
AU  - Khattab H
AD  - Faculty of Medicine Department of medical physiology, Tanta University, Tanta, 
      Egypt.
FAU - Alaarag, Ahmed
AU  - Alaarag A
AD  - Cardiovascular medicine department, Faculty of Medicine, Tanta University, Tanta, 
      31511, Egypt. ahmed.elaarag@med.tanta.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20221219
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Humans
MH  - Male
MH  - Echocardiography
MH  - *Heart Failure/physiopathology
MH  - Intercellular Adhesion Molecule-1
MH  - Stroke Volume
MH  - *Testosterone/deficiency
PMC - PMC9761962
OTO - NOTNLM
OT  - HFpEF
OT  - NYHA class
OT  - Testosterone
COIS- We do not have any conflict of interest to declare.
EDAT- 2022/12/19 06:00
MHDA- 2022/12/21 06:00
PMCR- 2022/12/19
CRDT- 2022/12/18 23:14
PHST- 2022/04/21 00:00 [received]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2022/12/18 23:14 [entrez]
PHST- 2022/12/19 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/12/19 00:00 [pmc-release]
AID - 10.1186/s12902-022-01249-3 [pii]
AID - 1249 [pii]
AID - 10.1186/s12902-022-01249-3 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 Dec 19;22(1):321. doi: 10.1186/s12902-022-01249-3.